Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.39 |
| ▸ | TUBB | P07437 | 1/20 | 0.39 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.39 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.39 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.39 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.39 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601414 | 0.84 | CYP3A4 (0.61) | IDO1CA2CA12CA1CA7 | |
| SCHEMBL11227602 | 0.83 | IDO1 (0.50) | IDO1CA2CA12CA1CA7 | |
| SCHEMBL791989 | 0.81 | IDO1 (0.63) | IDO1TSHRNPC1MAPTRAB9A | |
| SCHEMBL11242750 | 0.81 | TP53 (0.46) | CA2TP53TSHRGAACYP3A4 | |
| SCHEMBL15715963 | 0.80 | IDO1 (0.41) | IDO1CA2CA12CA1CA7 | |
| SCHEMBL11699485 | 0.78 | ALDH1A1 (0.46) | CA2TP53TSHRGAACYP3A4 | |
| SCHEMBL3787241 | 0.77 | TP53 (0.50) | CA2CA12CA1CA7CA9 | |
| SCHEMBL15732193 | 0.77 | IDO1 (0.41) | IDO1CA2TP53GAANPC1 | |
| SCHEMBL9875338 | 0.76 | CYP3A4 (0.67) | IDO1CA2CA12CA1CA7 | |
| SCHEMBL22889496 | 0.76 | IDO1 (0.42) | IDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110179777-B | Pharmaceutical compositions comprising nitroxyl donors | 卡尔迪奥克斯尔制药公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3427728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200163929-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190224159-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10245249-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3427728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | Cardioxyl Pharmaceuticals, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-22 | — | — | US | disclosed |
| EP-2945621-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-2558069-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2512478-A1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20120263753-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| EP-2440245-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | Novartis AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2011130379-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011084549-A1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-07-14 | — | — | WO | disclosed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | disclosed |
| EP-2268618-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010144734-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | IDO1 288/4885CA2 4041/4885CA12 4709/4885 |
| US-10245249-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | IDO1 288/4885CA2 4041/4885CA12 4709/4885 |
| US-20200163929-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | IDO1 288/4885CA2 4041/4885CA12 4709/4885 |
| US-20120263753-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | LY96, TLR3, GABRA4 | IDO1 548/4885CA2 3008/4885CA12 1791/4885 |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | IDO1 1432/4885CA2 2572/4885CA12 3590/4885 |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | HAMP, MAVS, MYD88 | IDO1 3202/4885CA2 3817/4885CA12 3836/4885 |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | IDO1 288/4885CA2 4041/4885CA12 4709/4885 |
| US-20190224159-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | IDO1 288/4885CA2 4041/4885CA12 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.